Event Details


Clovis Oncology’s Rucaparib Significantly Improved Progression-Free Survival in All Ovarian Cancer Patient Populations Studied in Phase 3 ARIEL3 Maintenance Treatment Trial
Monday, June 19, 2017 8:30 a.m. ET  
Webcast Presentation
Click here for webcast

Event Details
TitleClovis Oncology’s Rucaparib Significantly Improved Progression-Free Survival in All Ovarian Cancer Patient Populations Studied in Phase 3 ARIEL3 Maintenance Treatment Trial
Date and TimeMonday, June 19, 2017 8:30 a.m. ET